Shares of one biotechnology name drew fresh attention after new clinical data strengthened the outlook for its siRNA-targeting programs, according ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE